DE3855869T2 - Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern - Google Patents

Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern

Info

Publication number
DE3855869T2
DE3855869T2 DE3855869T DE3855869T DE3855869T2 DE 3855869 T2 DE3855869 T2 DE 3855869T2 DE 3855869 T DE3855869 T DE 3855869T DE 3855869 T DE3855869 T DE 3855869T DE 3855869 T2 DE3855869 T2 DE 3855869T2
Authority
DE
Germany
Prior art keywords
domain
infected cells
binding
hiv
hiv env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3855869T
Other languages
English (en)
Other versions
DE3855869D1 (de
Inventor
Phillip W Berman
Timothy J Gregory
Lawrence A Lasky
Gerald R Nakamura
Eric J Patzer
John S Patton
Ellen S Vitetta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE3855869D1 publication Critical patent/DE3855869D1/de
Application granted granted Critical
Publication of DE3855869T2 publication Critical patent/DE3855869T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3855869T 1987-02-20 1988-02-19 Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern Expired - Lifetime DE3855869T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1680987A 1987-02-20 1987-02-20
US5706187A 1987-06-01 1987-06-01
US15533688A 1988-02-12 1988-02-12

Publications (2)

Publication Number Publication Date
DE3855869D1 DE3855869D1 (de) 1997-05-22
DE3855869T2 true DE3855869T2 (de) 1997-10-02

Family

ID=27360648

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3855869T Expired - Lifetime DE3855869T2 (de) 1987-02-20 1988-02-19 Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern

Country Status (6)

Country Link
EP (1) EP0279688B1 (de)
AT (1) ATE151638T1 (de)
CA (1) CA1330038C (de)
DE (1) DE3855869T2 (de)
ES (1) ES2102347T3 (de)
GR (1) GR3024051T3 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
CA2003300A1 (en) * 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5731189A (en) * 1989-02-28 1998-03-24 New York University Human monoclonal antibodies to human immunodeficiency virus
EP0470184B1 (de) * 1989-04-25 1997-02-12 Tanox Biosystems, Inc. FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
GB8912496D0 (en) * 1989-05-31 1989-07-19 Medical Res Council Vaccines
CA2066607A1 (en) * 1989-09-22 1991-03-23 Thomas Kieber-Emmons Peptides associated with the cd4 binding region of gp120 and their methods of use
WO1991012021A2 (en) * 1990-02-13 1991-08-22 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
EP0527789A1 (de) * 1990-04-03 1993-02-24 Genentech, Inc. Hiv-hüllpolypeptide
JPH05507491A (ja) * 1990-05-16 1993-10-28 デイナ・フアーバー・キヤンサー・インステイテユート 免疫原性ペプチド、抗体、及び、ｃｄ４レセプター結合に関するそれらの用途
EP0554401A4 (en) * 1990-10-26 1996-10-30 New York Health Res Inst Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
US6228608B1 (en) 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
CA2114849C (en) * 1991-08-29 2007-04-24 Jay A. Berzofsky Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
CA2164505A1 (en) 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
JPH09504027A (ja) * 1993-10-22 1997-04-22 ジェネンテク，インコーポレイテッド ワクチンとしての使用のための抗原のマイクロカプセル化のための方法および組成物
WO1995011009A1 (en) * 1993-10-22 1995-04-27 Genentech, Inc. Method for preparing microspheres comprising a fluidized bed drying step
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4714613A (en) 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
ATE286132T1 (de) * 1984-10-18 2005-01-15 Pasteur Institut Dns-fragmente des gag-gens von lav
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
ATE138100T1 (de) 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
DE3672624D1 (de) 1985-02-05 1990-08-23 Us Commerce Verfahren zum nachweis von htlv-iii neutralisierenden antikoerpern in sera.
AU592258B2 (en) * 1986-12-30 1990-01-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins

Also Published As

Publication number Publication date
DE3855869D1 (de) 1997-05-22
GR3024051T3 (en) 1997-10-31
EP0279688A2 (de) 1988-08-24
CA1330038C (en) 1994-06-07
EP0279688A3 (de) 1989-09-13
EP0279688B1 (de) 1997-04-16
ES2102347T3 (es) 1997-08-01
ATE151638T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
ATE151638T1 (de) Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
US5013548A (en) Production of antibodies to HIV
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
GB2255093A (en) Hiv-1 core protein fragments
ATE132197T1 (de) Monoklonale antikörper
NZ516264A (en) Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
JPH07506810A (ja) 自己抗原である病原性のｔ細胞エピトープおよびｂ細胞エピトープに対する寛容性を誘導するための合成ペプチドの使用
JPS62501263A (ja) 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体
CN107427590A (zh) 具有多个t细胞表位的靶向部分肽表位复合物
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
RU2337922C9 (ru) ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП
He et al. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120–CD4 complex in transgenic mice that produce human immunoglobulins
US6268472B1 (en) Modified HGP-30 peptides, conjugates, compositions and methods of use
JPH05506142A (ja) Ｈｉｖ蛋白質の非免疫支配エピトープに特異的なモノクローナル抗体
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
US6258945B1 (en) HIV-1P-17 peptide fragments, compositions containing and methods for producing and using same
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
RU2221873C2 (ru) Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
KR920700698A (ko) 아메리카 자리콩 항바이러스성 단백질-모노클로날항체 결합체
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
JPH06506947A (ja) 抗ウィルスハイブリッド抗体
Lüscher et al. A 3β‐cholestanyl‐containing mono‐benzylpenicilloyl oligoamide and peptide suppress anti‐benzylpenicilloyl antibody formation in mice
CA2144936A1 (en) Antibody conjugates with improved properties
NZ503032A (en) Use of a binding agent to reconforming multi-epitopic antigens to initiate an immune response

Legal Events

Date Code Title Description
8364 No opposition during term of opposition